Frederiksberg Hospital
- Address
- lock Available on a paid plan
Cardiovascular Disease Research
At Frederiksberg Hospital, clinical trials in cardiovascular diseases focus on heart failure prevention and reducing the risk of major heart-related events. The research is centered on evaluating new treatment combinations that may better protect patients at elevated cardiovascular risk.
- Prevention of heart failure and cardiovascular death
- Testing new approaches to lower risk in high-risk patients
- Assessing treatment effectiveness for long-term heart protection
This work supports efforts to improve outcomes for people who may be vulnerable to serious cardiac complications.
Immune-Mediated and Inflammatory Disease Studies
The site is active in immune system diseases and musculoskeletal diseases, with trials in psoriatic arthritis and axial spondyloarthritis. These studies are designed to better control inflammation, ease joint and axial symptoms, and improve daily functioning for people living with chronic inflammatory conditions.
- Psoriatic arthritis and active psoriatic arthritis
- Axial spondyloarthritis and axial disease
- Evaluating new therapies to reduce inflammation and symptoms
Research at Frederiksberg Hospital also includes imaging-based assessment of inflammatory burden, helping to refine how treatment benefit is understood in rheumatic disease.
Psychiatry and Behavioral Health Research
In the area of psychiatry and psychology, the Lab of Neuropsychiatry is involved in trials addressing schizophrenia and alcohol use disorder. The main goal is to explore whether new treatment strategies can help reduce alcohol consumption and support better management of complex mental health needs.
- Schizophrenia with alcohol use disorder
- Improving management of co-occurring mental health and substance use problems
- Testing whether new therapies can reduce alcohol intake
This research reflects a growing focus on integrated care for patients with overlapping psychiatric and behavioral conditions.
Metabolic and Lipid Disorder Research
Trials in congenital, hereditary, and neonatal diseases and abnormalities and related metabolic conditions include work on severe hypertriglyceridemia. The research aims to determine whether new therapies can more effectively lower triglyceride levels and improve lipid control in affected patients.
- Severe hypertriglyceridemia
- Evaluating treatments to lower fasting triglycerides
- Improving management of metabolic risk
These studies contribute to better understanding and treatment of lipid disorders that can increase broader health risks.
Oncology and Urogenital Disease Research
The site also supports trials in male urogenital diseases and cancer research, including studies in metastatic castration-resistant prostate cancer. The purpose is to evaluate new treatment combinations and identify biomarkers that may help guide more effective care.
- Metastatic castration-resistant prostate cancer
- Testing combination approaches for advanced cancer
- Exploring biomarkers linked to treatment response
This area of research aims to improve options for patients with advanced prostate cancer who have limited treatment choices.
Skin, Connective Tissue, and Autoimmune Research
Clinical research in skin and connective tissue diseases overlaps with autoimmune conditions such as psoriatic arthritis. These trials are focused on finding therapies that can better control both skin-related and joint-related disease activity while improving overall patient quality of life.
- Psoriatic arthritis with skin and joint involvement
- Testing therapies for symptom relief and disease control
- Supporting more personalized treatment selection
The research reflects a broad interest in inflammatory diseases that affect multiple body systems.
Cross-Disciplinary Translational Research
Across its 10 clinical trials, Frederiksberg Hospital brings together cardiovascular, immunology, psychiatric, and metabolic research. The overall aim is to test new therapies, improve understanding of disease mechanisms, and support more effective treatment decisions across several chronic conditions.
- Multiple chronic disease areas studied in one hospital setting
- Evaluating treatment effectiveness and symptom improvement
- Linking clinical outcomes with better disease understanding
This diverse portfolio highlights a strong commitment to both patient care and clinical innovation.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 8 therapeutic areas and 15 of 23 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 5 by active trials.
- 1Region Hovedstaden2active
lock +4 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Janssen Cilag International4trials
lock +3 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 111 other sites in Denmark
Therapeutic Area Benchmark — Denmark
Select a therapeutic area to compare against other sites in Denmark.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Denmark
Market Share
Country: Denmark
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Frederiksberg Hospital
lock Showing 1 of 15 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Long-term Safety Extension Study of Mavacamten (MYK-461) in Adults with Hypertrophic Cardiomyopathy Who Have Completed the MAVERICKHCM (MYK-461-006) or EXPLORER-HCM (MYK-461-005) Trials (MAVA-LTE) | Myokardia Inc. | Phase III | Not Recruiting | Sep 2019 | Jan 2026 |
IMP list
lock Showing 1 of 23 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Isis 678354 Sodium Salt | 2 | Unknown | 2022-03-08 | 2023-07-12 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.